Riskpilot← Back to searchSign inGet full accessThePharmaTeam ApS
APSActiveCVR 42366358Nordre Fasanvej 215Engineering activities and related technical consultancy · NACE 7112Est. 20215 employees
Revenue 2024
DKK 6,8M
+9658% vs 2023
EBITDA margin
28.7%
+2701% vs 2023
Equity ratio
40.6%
Financial strength
Net profit 2024
DKK 1,5M
+1674% vs 2023
| Revenue | DKK 6,8M | +9658% |
| EBITDA | DKK 2M | +2701% |
| Net profit | DKK 1,5M | +1674% |
| Total assets | DKK 4M | +6% |
| Equity | DKK 1,6M | +1159% |
| Employees | 5 | — |
Legal name
ThePharmaTeam ApS
CVR number
42366358
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
6. maj 2021
Share capital
DKK 40.000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen.
Company purpose
Selskabets formål er udøvelse af konsulentvirksomhed inden for biostatistik og statistisk programmering samt at udøve enhver aktivitet, der efter ledelsens skøn er forbundet hermed.
Address
Nordre Fasanvej 215
Email
contact@thepharmateam.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | -28 | 41 | 70 | 6.796 |
| Staff expenses | -0 | -0 | -0 | -4.845 |
| EBITDA | -28 | 41 | 70 | 1.951 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | -28 | 41 | 70 | 1.951 |
| Net financials | -0 | -3 | -0 | -2 |
| Profit before tax | -28 | 38 | 69 | 1.948 |
| Tax | -5 | 11 | -14 | 466 |
| Net profit | -23 | 28 | 84 | 1.483 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 1.449 | 2.114 | 3.758 | 3.971 |
| Equity | 17 | 44 | 128 | 1.611 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 1.314 | 2.070 | 3.630 | 2.360 |
| Total debt | 1.314 | 2.070 | 3.630 | 2.360 |
EBITDA margin
28.7%
This company
15.8%
Market median
+82% vs market
20212024
Equity ratio
40.6%
This company
38.2%
Market median
+6% vs market
20212024
Return on equity
92.1%
This company
18.4%
Market median
+401% vs market
20212024
Net profit margin
21.8%
This company
8.1%
Market median
+169% vs market
20212024
Asset turnover
1.71×
This company
1.12×
Market median
+53% vs market
20212024
Debt / equity
1.47×
This company
0.62×
Market median
-137% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-05-06 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
BV Management | Management | 2024 |
JS Management | Management | 2023 |
EG Management | Management | 2021 |
GD Management | Management | 2024 |
| Former (1) | ||
ON Management | Management | 2021 – 2023 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 25–33.32% | 25–33.32% | 2024 | |
| Company | 25–33.32% | 25–33.32% | 2026 | |
| Company | 25–33.32% | 25–33.32% | 2024 | |
| Company | 25–33.32% | 25–33.32% | 2024 | |
| Company | 25–33.32% | 25–33.32% | 2024 | |
| Company | 20–24.99% | 20–24.99% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AndStats ApS
ThePharmaTeam ApS Board members of ThePharmaTeam ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bettina Vibeke Nielsen | Management | 0 companies |
| Jens-Kristian Slott Jensen | Management | 0 companies |
| Ole Nielsen | Management | 0 companies |
| Edith Gabriela Martinez Calderon Ravn | Management | 0 companies |
| Gitte Dam Jepsen | Management | 0 companies |